版本:
中国

BRIEF-Aerie Pharmaceuticals reports positive topline safety and efficacy results for rhopressatm

April 12 Aerie Pharmaceuticals Inc:

* Aerie Pharmaceuticals reports positive rocket 4 six-month topline safety and efficacy results for rhopressatm (netarsudil ophthalmic solution) 0.02pct

* Aerie Pharmaceuticals -most common rhopressa adverse event was hyperemia, which was reported in about 48 percent of patients, 75 percent of which was mild

* Aerie Pharmaceuticals Inc says 12-month safety data from mercury 1 are expected in Q3 of this year Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐